| Project/Area Number |
11671597
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | University of Tokyo |
|---|
Principal Investigator |
YOSHIKAWA Hiroyuki University of Tokyo Dept. of OB/GYN Assoc.Prof., 医学部・附属病院, 助教授 (40158415)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUMOTO Koji University of Tokyo Dept. of OB/GYN Associate, 医学部・附属病院, 助手 (30302714)
YASUGI Toshiharu University of Tokyo Dept. of OB/GYN Associate, 医学部・附属病院, 助手 (20251267)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,900,000)
Fiscal Year 2000: ¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 1999: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Human Papillomavirus (HPV) / variant / CIN / Cervical Cancer / L2 / neutralizing antibody / E6 / E7 / ヒトパピローマウイルス(HPV) / VLP / DNAワクチン / Variant |
|---|
| Research Abstract |
1. To see whether the expression of E6 and E7 genes is an essential finding in HPV-positive cervical carcinoma and cervical intraepithelial neoplasia (CIN), we constructed a RT-PCR assay using a pair of consensus primers in the E6 and E7 regions. The study demonstrates that E6 and E7 transcripts of HPV exist in virtually all HPV-positive cervical neoplasia specimens except for the absence of E7 transcripts in some of CINs.
2. To elucidate whether HPV16 E6 variations carry an elevated risk for cervical cancer in Japanese population, we investigated the E6 sequence variation in CINs and invasive cervical cancers. HPVE6 variants representd a significant risk factor is common between Western and Japanese women despite the different distribution of each variant.
3. We nasaly immunized Balb/c mice with a synthetic peptide with the 13 aa HPV 16 L2 sequences, and examined the antibodies elicited. The serum containing the IgG antibody and the vaginal wash containing the IgA antibody neutralized HPV16 pseudovirionx and HPV11 authentic virions. The results provide a basis for the development of a peptide vaccine against broad-spectrum of genital HPVs for humans.
|
